Related Experiment Video
Updated: Jun 10, 2026

Procedures for the Identification of SARS-CoV-2 Entry Inhibitors as Potential Antivirals using MLV-Based Pseudoviruses
Published on: February 27, 2026
A blueberry-derived polysaccharide inhibits SARS-CoV-2 papain-like protease and exhibits broad-spectrum
Guangyi Chen1,2, Chenxin Zhang1,3, Bo Feng3
1School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.
Abstract:
Vaccinium corymbosum (blueberry) is widely regarded as a functional food, the antiviral potential of blueberry polysaccharides has not yet been explored. In this study, a polysaccharide fraction designated 2B4 was isolated from blueberry fruits, and its potential inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro)-a key enzyme involved in viral replication and immune evasion-was examined in detail. Chemical analysis and spectrum analysis results showed that 2B4 is a heterogeneous polysaccharide with an average molecular weight of 54.074 kDa, can be characterised as an acidic, branched heteropolysaccharide, containing both neutral and uronic sugar residues. In vitro assays demonstrated that 2B4 strongly inhibited SARS-CoV-2 PLpro activity. Kinetic binding analysis further indicated that 2B4 directly interacts with PLpro. At the cellular level, 2B4 displayed excellent safety and dose-dependent inhibition of HCoV-OC43 replication. This work offers a new perspective and experimental foundation for the development of natural antiviral candidates from edible and medicinal plants.
Related Concept Videos
Coronavirus
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Inhibitors of Virion Maturation and Assembly
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Antiviral Nucleoside Inhibitors

